Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9Y4R8

UPID:
TELO2_HUMAN

ALTERNATIVE NAMES:
Protein clk-2 homolog

ALTERNATIVE UPACC:
Q9Y4R8; D3DU73; O75168; Q7LDV4; Q9BR21

BACKGROUND:
Telomere length regulation protein TEL2 homolog, known alternatively as Protein clk-2 homolog, is integral to the DNA damage response. It functions within the TTT complex to stabilize PIKK family proteins, contributing to cellular defense against DNA damage from various sources such as ionizing radiation, UV, and mitomycin C. It also plays a role in the folding of PIKKs in collaboration with HSP90, and is crucial for the maintenance and activity of mTORC1 and mTORC2 complexes, which dictate cell growth and survival signals.

THERAPEUTIC SIGNIFICANCE:
The association of Telomere length regulation protein TEL2 homolog with You-Hoover-Fong syndrome, a condition marked by profound developmental and intellectual disabilities, underscores the therapeutic potential of targeting this protein. Understanding its role could open doors to potential therapeutic strategies for managing this syndrome and enhancing patient outcomes.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.